An Open-label Multi-center Study of INO-3107 With Electroporation (EP) in Subjects With HPV-6- and/or HPV-11-associated Recurrent Respiratory Papillomatosis (RRP)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Apr 2025 According to an INOVIO Pharmaceuticals media release, company will present data from this study in an oral presentation at National HPV Conference (Indianapolis, IN).
12 Feb 2025 According to an INOVIO Pharmaceuticals media release, company plans plans to submit its biologics license application (BLA) for INO-3107 in mid-2025 and request rolling submission and priority review under the FDA's accelerated approval program, using data from this trial.
12 Feb 2025 According to an INOVIO Pharmaceuticals media release, Dr. Peter Belafsky, Director of the Center for Voice & Swallowing at UC Davis Health and a principal investigator on the trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com